We bounced off of the line as I suspected might happen. I am expecting TLRY to at least retest the $180 dollar region if not make new all time highs. I would not put it past the market.
Would not recommend a short right now, confirmation is needed.
BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which BioLineRx is developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation.
In January 2016, BioLineRx entered into a collaboration with MSD, known as Merck...
With the rapidly expanding prescription drug market, one may take a flyer out on this stock (Rite Aid). As most of you know Rite Aid sold a vast amount of their stores to Walgreens, but the real story is those stores that were sold were in key geographic locations and created large amounts of revenue. I have been tracking this stock since 2013, and the common...
AbbVie's bread winner is Humira - this drug accounts for the majority of their revenue. However, they did forecast that by 2020, revenue from Humira will be $21B - which is about 75% of their 2017 revenue of $28.22B.
Since AbbVie depends so heavily on their flagship, their stock is fairly volatile, giving this play more of a risk. Consider well-hedged positions...
Not sure if the BLUE support is gonna hold this time around. Might eventually sets on ~9yr-old support (note chart is in Log scale). Monthly chart also showing massive MACD divergence. As a result, sold my position to see how is gonna play out in the ST. Also binary outcome drug data expected this year, with unknown timing. However, INCY is top pick at Credit...
This is my first wave chart, so be gentle. :)
i have 2 scenario. One is that wave 5 have ended and we are ready to a correctional wave of A,B,C.
The other is that they will present bad revenue. And the price will continue the down trend, and stop at the support line at 6,49
where the 5th wave could end and start a correction of A,B,C.
Teva have a...
$CBIO Recent Highlights and Upcoming Milestones
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis...
There is one useful way to determine when a trend is over and that is using a 50% "speedline" of a move.
The decline from $400 in $IBB, the IShares Nasdaq Biotechnology Index Fund back in July 2015 and then tumbled 40% to $240 on February 9th, 2016 and later retested $240 on June 27, 2016.
The mid-point of that decline is $320 and a line drawn from...
The wave 2 correction in Mangalam Drugs seems to have become a bit complex. Now it appears to be at a structural support. Also there is 61% Fib support. So it's likely that the up move could start.
Any move below wave 1 low would negate this setup.
Consistent outperformer with always an Ace up its sleeve. Expect at least a 30% increase in value in 2016. You will never see this stock at these prices ever again. Buy now and thank me Later. All bets are off if we have a financial collapse dragging the share price below 92.96.
Harvard Apparatus Regentive Technology is a bioscience company working on more natural heart valve replacements and other pretty cool biotech stuff. However my interest is because the way they are ramping up for another go after moving from $0.60 to $3.25 in less than a month. This is shaping up to be your typical "head and shoulders" scenario. HART's 1day MACD...